FDA Inspection
GlaxoSmithKline BiologicalsGlaxoSmithKline Biologicals – FDA Inspection, Nov 13, 2018
Record Details
This FDA Inspection record concerns GlaxoSmithKline Biologicals, with an inspection on November 13, 2018, issued by the Office of Inspections and Investigations, covering biologics.
- People
- Lily Y. Koo (Issuing Officer)
- Randa Melhem (Company Rep)
View Company Profile
ID · b7cb345e-7492-4016-bfb2-29932766b0e4
Inspection Facts
- Inspection number
- 1074672
- FDA center
- Biologics
- Outcome
- Form 483 issued
Other FDA inspections of GlaxoSmithKline Biologicals
3| Date | Classification | Office | Project area |
|---|---|---|---|
| June 4, 2024 | Not classified | Office of Inspections and Investigations | |
| March 12, 2024 | VAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| September 13, 2022 | VAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
Other documents for GlaxoSmithKline Biologicals
- FDA Inspection 1242355 - 2024-06-04
- FDA Inspection 1232702 - 2024-03-12
- FDA Inspection 1179634 - 2022-09-13
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.